Passive positioning systems play an essential role in the field of electronic countermeasures. Many factors affect the efficiency of passive positioning systems, especially the deployment of its observatories station. In this paper, the genetic algorithm based on bi-level selection is proposed to solve the deployment optimization problem of the time difference of arrival for a passive positioning system in three-dimensional space. In this paper, three sets of comparison experiments are set up to determine the superiority of the proposed algorithm. The experimental results show that the improved genetic algorithm can be well applied to the deployment of three-dimensional time difference of arrival positioning, and the proposed bi-level selection operation is clarified which has a great effect on promoting the convergence of the algorithm.
Currently, the transcript abundance of key enzymes for chemotherapy drug metabolism, which may help in predicting the efficacy of a drug, can easily be detected in tumor tissues. However, there has been little research on the enzymes involved in the
Long stress-induced noncoding transcripts 5 (LSINCT5) has been reported to be upregulated in several human cancers and related to poor prognosis. However, its involvement in esophageal squamous cell carcinoma (ESCC) remains largely unknown. We aim to evaluate the expression and putative role of LSINCT5 on the progression of ESCC.LSINCT5 expression was first examined in the ESCC cell lines using RT-qPCR, and the next-generation RNA-Seq technology was employed to analyze and functionally annotate the differential gene expression before and after LSINCT5 knockdown in ESCC was made. Based on the functional annotation results, the effects of LSINCT5 knockdown on cell growth, migration, invasion, and epithelial-to-mesenchymal transition (EMT) were assessed in the ESCC cell lines. Finally, the expression and clinicopathological significance of LSINCT5 in ESCC and corresponding nontumor tissues were further explored using RT-qPCR.The RT-qPCR results showed that LSINCT5 expression was significantly upregulated in the ESCC cell lines. The differential gene expression analysis by next-generation RNA-Seq showed that 138 genes were up-regulated, and 227 genes were downregulated after LSINCT5 was knocked down in the ECA 109 cells. In addition, the functional annotation revealed that the differentially expressed genes were mainly functionally involved in tight junctions, ECM-receptor interactions, and MAPK signaling pathway. Further in vitro studies indicated that the knockdown of LSINCT5 significantly suppressed proliferation, migration, invasion, and EMT in ESCC cells. Finally, a comparative study of paired ESCC and corresponding nontumor tissues showed that LSINCT5 was upregulated in the ESCC tissues, and the increased LSINCT5 expression was related to late clinical stages, large tumor sizes, and lymph node metastasis.The results indicate that LSINCT5 is upregulated in ESCC and may act as an oncogene promoting the progression of ESCC.
To explore the better therapy in the treatment of ganglion.Ninety cases of ganglion were randomized into a two-way quintuple puncture group, a common quintuple puncture group and a fire needling group, 30 cases in each one. In the two-way quintuple puncture group, the "9-in-1" multiple penetrating needling technique was used. In the common quintuple puncture group, the traditional "5-in-1" multiple penetrating needling technique was applied. In the fire needling group, the traditional multiple fire needling technique was adopted. The treatment was given once a day, 3 treatments made one session and the efficacy was analyzed statistically after 1 session treatment in the three groups.All of the three therapeutic methods achieved the efficacy on ganglion. The curative rate was 96. 7% (29/30) in the two-way quintuple puncture group, which was better obviously than 66.7% (20/30) in the common quintuple puncture group and 60. 0% (18/30) in the fire needling group (both P<0. 01).The two-way quintuple puncture technique achieves the remarkably superior efficacy on ganglion as compared with the common quintuple puncture technique and fire needling technique.
objective . To transfect the hBDNF (human brain-derived neurotrophic factor) gene into CHO cells, es- tablish a stable expression system, and to detect the biological activity of the expressed hBDNF protein. Methods. Liposomes were used to mediate the transfection, and RT-PCR, Western-blotting and MTT method were to de- tect. Results. hBDNF mRNA was detected in the transfected CHO cells, and hBDNF protein, promoting PC12 cells' growth, can be detected in the supernatant. Conclusion. The stable expression system of hBDNF-CHO was successfully established, which could produce hBDNF protein with biologic activity. (Life Science Journal. 2006; 3 (3):49-52J (ISSN: 1097-8135).
Objective: Gene therapy on the glioma has been studied for many years, but most studies still remain at the level of single gene therapy. However, the glioma is characterized by a multistep process of genetic and molecular changes to oncogenes and tumor suppressor genes, which limits the efficacy of single gene-mediated therapy due to the difficulty of finding a pivotal gene conferring its occurrence in glioma gene therapy. In this paper, we try to study the anti-tumor effects and mechanism of a recombinant adenoviral vector co-expressing leukemia inhibitory factor (LIF) and interleukin-24 (IL-24) on glioma cells. Materials and Methods: LIF/IL-24 bicistronic adenovirus (Ad-LIF-IL-24) was constructed and preserved by our laboratory. The enhanced growth-suppressing and apoptosis-inducing effect of Ad-LIF-IL-24 on the U251 glioma cells in vitro was assessed, and the expressions of the apoptosis-related genes (bcl-2, bax, and ICE) were determined. Results: Ad-LIF-IL-24 could induce much more cellular apoptosis of U251 glioma cells than either Ad-LIF or Ad-IL-24 alone at the same virus titer. Molecularly, Ad-LIF-IL-24 could significantly enhance the expressions of bax and ICE though it inhibits the expression of bcl-2. Conclusion: Cancer gene therapy combining LIF and IL-24 may constitute a novel and more effective therapeutic strategy for gliomas, with good potential prospects of clinical application.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)